First Wave BioPharma shares are trading higher after Roth MKM maintained a Buy rating on the stock and adjusted its target from $11 to $40.
Portfolio Pulse from Benzinga Newsdesk
First Wave BioPharma's stock (FWBI) is trading higher following Roth MKM's decision to maintain a Buy rating and increase the price target from $11 to $40.

January 03, 2024 | 7:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
First Wave BioPharma's stock price is likely to experience a positive short term impact due to Roth MKM's maintained Buy rating and significant price target increase from $11 to $40.
Analyst ratings and price target adjustments are strong indicators that can influence investor sentiment and stock prices. The substantial increase in the price target for FWBI by Roth MKM suggests a strong conviction in the company's future performance, which can lead to increased investor interest and a rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100